Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) and keeping the price target at $80.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the potential of Structure Therapeutics, Inc.’s aleniglipron in the competitive landscape of oral GLP-1 drugs. The decision by Pfizer to withdraw danuglipron due to liver toxicity and the promising results from Lilly’s orforglipron trial have set a benchmark for aleniglipron. Aleniglipron’s unique structural properties and its clear safety profile provide it with a competitive edge, suggesting it could achieve significant weight loss results in upcoming trials.
Furthermore, the pharmacokinetics of aleniglipron, which allow for rapid exposure and a manageable side effect profile, support its potential for achieving target weight loss. The drug’s differentiated effects, spanning from metabolic disorders to Type 2 diabetes, enhance its market penetration prospects. These factors, combined with the challenges faced by new entrants in penetrating established markets, underpin Ghosh’s optimistic outlook for the stock.
In another report released on April 15, JMP Securities also reiterated a Buy rating on the stock with a $87.00 price target.